Author(s): Barnett D, Granger V, Whitby L, Storie I, Reilly JT
Abstract Share this page
Abstract To determine the potential advantage of single-platform technology in the enumeration of CD4+ T lymphocyte and CD34+ stem cells, data has been analysed from the UK NEQAS for Leucocyte Immunophenotyping schemes. The inter-laboratory CVs for CD4+ T lymphocyte counts were consistently lower for single-platform (mean 13.7\%, range 10-18.3\%) compared to dual-platform methodology (mean 23.4\%, range 14.5-43.7\%). Subgroup analysis of single-platform users demonstrated mean overall inter-laboratory CVs of 17.2\%, 13\% and 7.1\% for the FlowCount, TruCount and volumetric approach respectively. The lowest inter-laboratory CVs obtained for a single sample by each single platform approach were 4\% (TruCount), 4.4\% (volumetric), 4.6\% (FACSCount) and 12.7\% (FlowCount). Similarly, the mean inter-laboratory CV for CD34+ stem cell enumeration using non-standardized single-platform approaches was 18.6\% (range 3.1-36.9\%) compared to 28.6\% (range 19-44.2\%) for the dual-platform technology. Our results suggest absolute cell subset enumeration should be performed by single-platform technology and that such an approach should improve the quality control of multi-centre clinical trial data for CD4+ T lymphocyte and CD34+ stem cells.
This article was published in Br J Haematol
and referenced in Journal of Blood Disorders & Transfusion